TD Cowen Reiterates Buy Rating on ABCL After AbCellera Biologics Dosed First Participants of ABCL575

Group 1 - AbCellera Biologics Inc. is recognized as one of the 12 best NASDAQ penny stocks to buy according to hedge funds [1] - TD Cowen has reiterated a Buy rating on AbCellera without providing a price target [1] - The company is focusing on expanding its internal pipeline and strengthening partnerships through the Biosecure program, which are seen as catalysts for growth [2] Group 2 - AbCellera has initiated a Phase 1 clinical trial for ABCL575, a next-generation antibody treatment for moderate-to-severe atopic dermatitis, with data expected in mid-2026 [2] - The company is well-positioned financially and operationally, allowing it to invest in strategic initiatives like ABCL575 [3] - AbCellera specializes in discovering and developing antibody-based treatments for unmet medical needs in the U.S. [4]